Sjögren-szindróma: vizsgálatok itt: Olaszország
10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 13.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleTwo Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Where
- Cuneo, Pisa, Rome, Rozzano, Udine
- Életkor
- 18 év and over
- People
- 570 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07621809 · EU 2025-522271-29-00 - 2. fázisTaking peopleA Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
- Where
- Rome, Rozzano, Udine
- Életkor
- 18 év to 100 év
- People
- 344 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07737743 · EU 2025-524513-92-00 - 3. fázisTaking peoplePhase 3 Study of Telitacicept in Active Primary Sjögren's Disease
- Where
- Ancona, Milan, Rome, Rozzano
- Életkor
- 18 év to 75 év
- People
- 250 worldwide
- Run by
- Vor Biopharma
See details and how to joinNCT07404865 · EU 2026-525556-28-00 - 2. fázisNot yet taking people in OlaszországA randomized, parallel-group, open-label, Phase IIb pilot trial to evaluate the effectiveness in reducing systemic disease activity with methotrexate compared with hydroxychloroquine in adult male and female participants with moderate-to-severe primary Sjögren’s disease (MOSAIC STUDY)
- Where
- Pescara, Rome, Turin
- Életkor
- 18 év and over
- People
- 70
- Run by
- Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata Fon
See details and how to join2026-526767-38-00 - 1. fázisTaking peopleA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
- Where
- Roma
- Életkor
- 18 év and over
- People
- 36 worldwide
- Run by
- Cullinan Therapeutics Inc.
See details and how to joinNCT07041099 - 2. fázisTaking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Brescia, Milan, Rome
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00 - 1. fázisTaking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Ferrara, Rozzano
- Életkor
- 18 év to 70 év
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00 - 1. fázisTaking peopleA Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease
- Where
- Naples, Rome
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- Cullinan Therapeutics Inc.
See details and how to join2025-521462-96-00 - 3. fázisTaking peopleA Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- Where
- Catania, Florence, Milan, Pisa, Reggio Emilia, Rome, Turin, Udine, Verona
- Életkor
- 18 év and over
- People
- 844 worldwide
- Run by
- Amgen
See details and how to joinNCT06747949 · EU 2024-517513-32-00 - No phaseTaking peopleUltra-High Frequency Ultrasonography in Sjögren's Syndrome
- Where
- Pisa
- Életkor
- 18 év and over
- People
- 800
- Run by
- University of Pisa
See details and how to joinNCT06338735